Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pathological changes of prolactinomas treated with bromocriptine]

A Teramoto, K Takakura, T Fukushima

    No Shinkei Geka. Neurological Surgery
    |June 1, 1982
    PubMed
    Summary

    Bromocriptine treatment in prolactinomas initially suppresses prolactin synthesis and release. Long-term use causes shrinkage of hormone-producing cell organelles, leading to tumor reduction.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Clinicopathological and immunohistochemical analysis of the risk factors of recurrence of atypical lipomatous tumor/well-differentiated liposarcoma of the extremities.

    Acta orthopaedica Belgica·2025
    Same author

    Oral Health Interventions in Natural Disasters: A Scoping Review.

    Disaster medicine and public health preparedness·2023
    Same author

    Investigation of factors related to the occurrence of osteochondral lesions of the talus by 3D bone morphology of the ankle.

    The bone & joint journal·2018
    Same author

    A transfection method for short interfering RNA with the lipid-like self-assembling nanotube, A6K.

    Medical molecular morphology·2013
    Same author

    Preoperative embolization of meningiomas with N-butyl cyanoacrylate.

    Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences·2012
    Same author

    Ki-67 and minichromosome maintenance-7 (MCM7) expression in canine pituitary corticotroph adenomas.

    Domestic animal endocrinology·2011

    Area of Science:

    • Endocrinology
    • Pathology
    • Oncology

    Background:

    • Prolactinomas are pituitary tumors that overproduce prolactin.
    • Bromocriptine is a dopamine agonist used to treat prolactinomas.

    Purpose of the Study:

    • To investigate the pathological changes in prolactinomas treated with bromocriptine.
    • To elucidate the mechanism of bromocriptine-induced prolactinoma shrinkage.

    Main Methods:

    • Studied 12 prolactinoma cases using immunocytology and electron microscopy.
    • Analyzed short-term (days) and long-term (months) bromocriptine treatment effects.

    Main Results:

    • Short-term treatment: reduced prolactin staining, decreased exocytosis, abundant granules.

    Related Experiment Videos

  • Long-term treatment: absence of prolactin, infrequent granules, shrunken Golgi and ER, degenerative changes.

    • Conclusions:

    • Bromocriptine inhibits prolactin release and suppresses synthesis.
    • Prolonged treatment leads to organelle shrinkage and tumor reduction via sustained inhibition.